January 17, 2018 / 1:00 PM / a month ago

BRIEF-Biolinerx Announces Partial Monotherapy Results From Phase 2A Combat Study In Pancreatic Cancer

Jan 17 (Reuters) - Bioline Rx Ltd:

* BIOLINERX ANNOUNCES PARTIAL MONOTHERAPY RESULTS FROM PHASE 2A COMBAT STUDY IN PANCREATIC CANCER

* BIOLINE RX LTD - DATA TO BE PRESENTED AT UPCOMING ASCO-GI CONFERENCE; TOPLINE CLINICAL RESULTS EXPECTED BY H2 2018 AS PLANNED

* BIOLINE RX LTD - BL-8040 MONOTHERAPY RESULTED IN INCREASED INFILTRATION OF T CELLS INTO TUMOR

* BIOLINE RX LTD - PARTIAL RESULTS FROM BL-8040 MONOTHERAPY PORTION OF COMBAT TRIAL SHOW THAT BL-8040 WAS SAFE AND WELL-TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below